Oribiotech

Ori Biotech is an innovator in Cell and Gene Therapy manufacturing, delivering scalable solutions to address the critical needs of therapeutics developers.

[Oribiotech @OriBiotech]

We are excited to announce a partnership with CTMC, a joint @IncResilience & @MDAndersonNews venture, to accelerate novel cell therapy delivery. 🙌

We are looking forward to working together to enable widespread patient access to cell therapies.

➡️ https://t.co/hvq9zFqyUC

[Oribiotech @OriBiotech]

IRO® has received FDA Advanced Manufacturing Technology designation.

One of the first CGT platforms to earn this recognition, IRO supports more reliable, scalable and cost-effective manufacturing.

Read more 👉https://t.co/HxSWUG17Wn

[Oribiotech @OriBiotech]

Scaling CGT shouldn’t mean starting from scratch.

IRO® is a closed, modular system that grows with you from R&D to GMP. Its stackable design delivers more batches per square foot, boosting throughput while reducing timelines and costs.

🔗 Whitepaper ➡️ https://t.co/IQ2nqswKKq

[Oribiotech @OriBiotech]

Like many patients that face a lymphoma diagnosis, 83-year-old Navy veteran Mark Daniels was stunned.

Supported by the team at @JTCancerCenter, Mark received CAR-T therapy. He has since entered remission & is rebuilding strength.

Mark's full story ➡️ https://t.co/ctbjYaYfUx

[Oribiotech @OriBiotech]

Manufacturing must be designed for scale from day one to meet patient demand.

IRO® was developed with this in mind. As a modular platform it integrates best-of-breed technologies to support scalable, adaptable manufacturing.

Read our Whitepaper 👉 https://t.co/IQ2nqswKKq

[Oribiotech @OriBiotech]

New research from @UNIGE_en shows CD4 T cells may be powerful cancer killers, not just “helpers.”

Engineered CD4s wiped out tumours across melanoma, lung, ovarian, sarcoma, and brain cancers while sparing healthy tissue.

Read more 👉 https://t.co/YE8b2TFoY9

[Oribiotech @OriBiotech]

Conventional manufacturing methods for cell therapy products have limitations that mean development cannot keep pace with demand, according to Kumar from @MoffittNews in his recent chat with @Ori_JCFoster on the Ori Spotlight Podcast.

🎧Listen now: https://t.co/KnTxHwUNs7

[Oribiotech @OriBiotech]

Life took an unexpected turn for Jan Janisch-Hanzlik when a strange sensation in her toes was later diagnosed as MS.

Jan was enrolled in a first-of-its-kind trial using CAR-T cell therapy at @UNLincoln, now she’s feeling positive about the future ⬇️
https://t.co/5oUXb5oGLh

[Oribiotech @OriBiotech]

The @alliancerm has released its Q2 2025 Sector Snapshot, covering clinical, regulatory and commercial progress across the CGT space.

Here are our 5 key takeaways ⬇️

[Oribiotech @OriBiotech]

Building CGT manufacturing capacity that is fast, consistent, and cost-effective is critical.

In our webinar with @ElevateBio, we shared new data demonstrating how IRO® delivers superior biological performance & enables scalable manufacturing ⬇️
https://t.co/caBvZYoSaM

[Oribiotech @OriBiotech]

On the @BeginnersMindShow, @JasonCFoster joined @ChristianSoschner to discuss how automation & distributed manufacturing can reduce slow, manual steps that drive up costs & limit access to CGTs.

Watch the full episode: https://t.co/C3UvF3QHL5

[Oribiotech @OriBiotech]

Last week, we welcomed a group of high school students into our labs for Biotech Sprint for ELISA day!

They spent the afternoon exploring cell therapy, learning how to handle cell cultures, and peering down microscopes.

Thank you to everyone involved for making it possible!

[Oribiotech @OriBiotech]

Avoiding rigid manufacturing systems that force science to conform to infrastructure is critical to prevent limiting therapeutic potential.

IRO® has a modular design that delivers quality, flexibility & scalability, without tradeoffs.

Read our whitepaper:https://t.co/IQ2nqswKKq

[Oribiotech @OriBiotech]

What will it take to make CGTs commercially viable at scale?

At BIO '25, @Ori_JCFoster joined a @biospace panel to discuss how tech & timing shape success.

Flexible systems like IRO® are key, enabling scale while preserving biological performance.

🔗 https://t.co/qReJS9j3sZ

[Oribiotech @OriBiotech]

The success of CGT hinges on research, development & manufacturing being aligned.

Kumar Karyampudi, SD of Cell Therapies at @MoffittNews, joins @Ori_JCFoster to talk about infrastructure & how connecting R&D with GMP early, sets teams up for success.

🎧 https://t.co/KnTxHwUNs7

[Oribiotech @OriBiotech]

Hear Kale Feeter present at the @_CellandGene
Tech Expo tomorrow!

Kale will share how IRO® helps therapy developers scale faster, without compromising biological performance.

🗓️08/12
⏰10–12 ET
💻Register: https://t.co/4UpuHA0aGy

Learn more about IRO: https://t.co/GaB5LYaRPA

[Oribiotech @OriBiotech]

After battling CNS lymphoma twice, Jacquie turned to CAR-T in 2022. With her biomedical background, she trusted the science and her body’s strength.

She’s now in full remission and advocating for wider #PatientAccess across the UK.

Read her story: https://t.co/DIJe5NiYMR

[Oribiotech @OriBiotech]

A new “leukemia-on-a-chip” platform from @Penn and @nyuniversity replicates human bone marrow in 3D, enabling real-time observation of CAR-T behavior, resistance, and relapse.

It offers a faster, more personalised way to test and optimise therapies.

🔗 https://t.co/lfMQsb6oP7

[Oribiotech @OriBiotech]

On Wednesday, @ElevateBio joins us to explore how automated platforms like IRO® are improving biological performance & accelerating scale-up from R&D to GMP.

📅 Wednesday, August 6, 2025
🕐 11:00 AM ET
🌐 Register online at https://t.co/caBvZYoSaM

[Oribiotech @OriBiotech]

After relapsing from lymphoma, Gina, became the 100th CAR-T patient at @CedarsSinai.

Two days post-treatment, she was walking the halls. Now, she’s in remission and back home in her garden.

🌱 https://t.co/2wV8a1KLE8

[Oribiotech @OriBiotech]

Too often, CGT automation is built around engineering limits, not biology.

IRO® changes that. It’s designed to deliver superior cell quality across workflows & scale, giving teams the control to build around science, not compromise it.

Our whitepaper: https://t.co/IQ2nqswKKq